news
HexemBio raises $15.5M for stem cell rejuvenation
Berkeley-based HexemBio secured $15.5 million to expand its stem cell rejuvenation platform beyond transplant medicine. They're developing an injectable and a skin treatment that use a patient's own aging blood stem cells, briefly placing them in a lab-built environment to reset their biological clock.
Berkeley-based HexemBio secured $15.5 million to expand its stem cell rejuvenation platform beyond transplant medicine. They're developing an injectable and a skin treatment that use a patient's own aging blood stem cells, briefly placing them in a lab-built environment to reset their biological clock.
The architecture take
I'm always watching for longevity plays that go beyond supplements and gadgets. HexemBio's approach to stem cell rejuvenation is genuinely interesting because they're not just adding new cells; they're trying to reset your own existing cells, taking them back to a younger state. The idea is to make them behave like they did when they were first made, which is a neat trick. Right now, this tech is used for transplant patients, but the jump to a cosmetic injectable or a skincare product is the real market signal here. It tells me that the quest for biological age reversal is about to get a lot more invasive, and probably a lot more expensive. Expect to see 'rejuvenated' cells show up in clinics claiming to turn back your internal clock, not just your face. The price tag for that kind of reset will be eye-watering.